# A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

> clinical trial · VERIFIED · 2026-08-06

Status: RECRUITING · Sponsor: Eikon Therapeutics · Condition: Non Small Cell Lung Cancer (Squamous or Non Squamous)

- Company: Eikon Therapeutics
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07365319

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.